Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

The IMpower-132 trial for non small cell lung cancer

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer...

The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with...

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve...

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )

Combination strategies of immunotherapy in breast cancer

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...

Dr David R. Spigel - Tennessee Oncology, Nashville, USA

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )

20 year followup on high-dose chemo with HSCT in high-risk breast cancer

Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands

20 year followup on high-dose chemo with HSCT in high-risk breast cancer ( Dr Tessa Steenbruggen - Netherlands Cancer Institute, Amsterdam, Netherlands )

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )

Cardiac events in stage III NSCLC treated in daily clinical practice

Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

Cardiac events in stage III NSCLC treated in daily clinical practice ( Dr Juliette Degens - Academisch Ziekenhuis Maastricht, Maastricht, Netherlands )

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for...

Dr Maria Vittoria Dieci - University of Padua, Padova, Italy

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer ( Dr Maria Vittoria Dieci - University of Padua, Padova, Italy )

Liquid biopsy as a monitoring tool for the benefit of chemotherapy...

Dr Laura Bonanno - University of Padova, Padova, Italy

Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC ( Dr Laura Bonanno - University of Padova, Padova, Italy )

Key developments in prostate cancer

Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto...

Key developments in prostate cancer ( Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Dr Mark Beresford )

More from ecancer